title: Perioperative blood transfusions and decreased long-term survival in esophageal cancer.
abstract: We evaluated retrospectively the effect of perioperative blood transfusions on survival in esophageal cancer. The records of all patients who underwent esophageal resection (n = 316) at UCLA Medical Center from 1970 to 1993 were reviewed. Statistical analysis included univariate (log-rank chi 2) and multivariate (Cox proportional hazards) analyses with other known risk factors. High-volume blood transfusions (> 8 units) but not low-volume blood transfusions (1 to 8 units) were associated with a significant decrease in long-term survival (median survival: no transfusion, 22 months; low-volume blood transfusion, 14.5 months, versus high-volume blood transfusions, 6.5 months; p < 0.01). Multivariate analysis revealed that the shorter survival with high-volume blood transfusions was a result of an increased number of postoperative complications. High-volume blood transfusions were not associated with increases in tumor recurrence or infectious complications. The association between shorter survival and high-volume blood transfusions in esophageal cancer may, therefore, be because of the circumstances necessitating transfusion rather than any immunosuppressive effects of the transfused blood. These findings suggest that the transfusion of blood does not by itself decrease the chance of cure after esophageal resection.
authors: Department of Surgery, University of California, Los Angeles Medical Center, USA.
authors: S G
authors: SG
authors: Swisher
authors: E C
authors: EC
authors: Holmes
authors: K K
authors: KK
authors: Hunt
authors: J A
authors: JA
authors: Gornbein
authors: M J
authors: MJ
authors: Zinner
authors: D W
authors: DW
authors: McFadden
mesh_terms: D000230:Adenocarcinoma / Q000601:surgery; D001424:Bacterial Infections; D001803:Blood Transfusion / Q000706:statistics & numerical data; D001810:Blood Volume; D002294:Carcinoma, Squamous Cell / Q000601:surgery; D000077324:Crystalloid Solutions; D017707:Erythrocyte Transfusion; D004938:Esophageal Neoplasms / Q000601:surgery*; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007552:Isotonic Solutions; D016014:Linear Models; D015141:Los Angeles / Q000453:epidemiology; D008297:Male; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D010949:Plasma; D010952:Plasma Substitutes / Q000627:therapeutic use; D017713:Platelet Transfusion; D011183:Postoperative Complications; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D012709:Serum Albumin / Q000627:therapeutic use; D015996:Survival Rate; D065227:Transfusion Reaction
chemical_list: D000077324:Crystalloid Solutions; D007552:Isotonic Solutions; D010952:Plasma Substitutes; D012709:Serum Albumin